Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Middleton, Peter G., Mall, Marcus A., Dřevínek, Pavel, Lands, Larry C., McKone, Edward F., Polineni, Deepika, Ramsey, Bonnie W., Taylor-Cousar, Jennifer L., Tullis, Elizabeth, Vermeulen, François, Marigowda, Gautham, McKee, Charlotte M., Moskowitz, Samuel M., Nair, Nitin, Savage, Jessica, Simard, Christopher, Tian, Simon, Waltz, David, Xuan, Fengjuan, Rowe, Steven M., Jain, Raksha·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1908639

Cited by (2,225)

Items 201–300 of 2,225

An Update on CFTR Modulators as New Therapies for Cystic Fibrosis
John A. King, Anna-Louise Nichols, Siân Bentley, S.B. Carr, Jane Carolyn Davies · 2022 · Pediatric Drugs
Effects of a Partially Supervised Conditioning Program in Cystic Fibrosis: An International Multicenter, Randomized Controlled Trial (ACTIVATE-CF)
Helge U. Hebestreit, Susi Kriemler, Christian Schindler, Lothar Stein, Chantal Karila, Don S. Urquhart, David M. Orenstein, Larry C. Lands, Jonathan Schaeff, Ernst Eber et al. · 2021 · American Journal of Respiratory and Critical Care Medicine
Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study
Insa Korten, Elisabeth Kieninger, Linn Krueger, Marina Bullo, Christa E. Flück, Philipp Latzin, Carmen Casaulta, Claudia Boettcher · 2022 · Frontiers in Pediatrics
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment
Edith T. Zemanick, Bonnie W. Ramsey, Dorota Sands, Edward F. McKone, Isabelle Fajac, Jennifer L. Taylor‐Cousar, Marcus Alexander Mall, Michael W. Konstan, Nitin Nair, Jiaqiang Zhu et al. · 2025 · Journal of Cystic Fibrosis
Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis
Emily DiMango, Daniel B. Spielman, Jonathan B. Overdevest, Claire L. Keating, Sarah Fracasso Francis, David Dansky, David A. Gudis · 2020 · International Forum of Allergy & Rhinology
Rethinking physical exercise training in the modern era of cystic fibrosis: A step towards optimising short-term efficacy and long-term engagement
Mathieu Gruet, ZOE LOUISE SAYNOR, Don S. Urquhart, Thomas Radtke · 2021 · Journal of Cystic Fibrosis
Treatment Preference Among People With Cystic Fibrosis
Rory A. Cameron, Daniel Office, Jessie Matthews, Mark Rowley, Janice Abbott, Nicholas J. Simmonds, Jennifer A. Whitty, S.B. Carr · 2022 · CHEST Journal
CFTR Modulators: Current Status and Evolving Knowledge
Lucile Regard, Clémence Martin, Jennifer Da Silva, Pierre‐Régis Burgel · 2022 · Seminars in Respiratory and Critical Care Medicine
Improved glucose tolerance after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis
Carolin Steinack, Matthias Ernst, Felix Beuschlein, René Hage, Maurice Roeder, Macé Matthew Schuurmans, Christoph Schmid, Thomas Gaisl · 2023 · Journal of Cystic Fibrosis
Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER study
Jochen Georg Mainz, Karen Lester, Basil Elnazir, Michael Williamson, Edward F. McKone, D. Cox, Barry M. Linnane, Carlos Zagoya, Franziska Duckstein, Anton Barucha et al. · 2023 · Journal of Cystic Fibrosis
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or twoF508delalleles
Mirjam Stahl, Martha Dohna, Simon Y. Graeber, Olaf Sommerburg, Diane Miriam Renz, Sophia Theres Pallenberg, Andreas Voskrebenzev, Katharina Schütz, Gesine Hansen, Felix Doellinger et al. · 2024 · European Respiratory Journal
The human respiratory tract microbial community structures in healthy and cystic fibrosis infants
Marie‐Madlen Pust, Lutz Wiehlmann, Colin Davenport, Isa Rudolf, Anna‐Maria Dittrich, Burkhard Tümmler · 2020 · npj Biofilms and Microbiomes
Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis
Madalena C. Pinto, Iris A. L. Silva, Miriam Frankenthal Figueira, Margarida Duarte Amaral, Miquéias Lopes‐Pacheco · 2021 · Journal of Experimental Pharmacology
Fertility, Pregnancy and Lactation Considerations for Women with CF in the CFTR Modulator Era
Raksha Jain, Jennifer L. Taylor‐Cousar · 2021 · Journal of Personalized Medicine
Realizing the Dream of Molecularly Targeted Therapies for Cystic Fibrosis
Francis S. Collins · 2019 · New England Journal of Medicine
Small-molecule drugs for cystic fibrosis: Where are we now?
Onofrio Laselva, Lorenzo Guerra, Stefano Castellani, Maria Favia, Sante Di Gioia, Massimo Conese · 2021 · Pulmonary Pharmacology & Therapeutics
Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: A scoping review
Mitchell L. Ramsey, Susan S. Li, Luis F. Lara, Yevgeniya Gokun, Venkata Sandeep Akshintala, Darwin L. Conwell, John Heintz, Stephen E. Kirkby, Karen McCoy, Georgios I. Papachristou et al. · 2022 · Journal of Cystic Fibrosis
Individualized approach to elexacaftor/tezacaftor/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series
Hisham Ibrahim, Hammad Danish, David J. Morrissey, Kevin Frederick Deasy, M. J. H. McCarthy, James Dorgan, C. Fleming, Ciara Howlett, Sarah Twohig, Tamara Vagg et al. · 2023 · Frontiers in Pharmacology
Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor
Sonia Graziano, Francesca Boldrini, Gaia Romana Pellicano, Francesco Milo, Fabio Majo, Luca Cristiani, Enza Montemitro, Federico Alghisi, Sergio Bella, Renato Cutrera et al. · 2023 · CHEST Journal
PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study
Martha Dohna, Andreas Voskrebenzev, Filip Klimeš, Till F. Kaireit, Julian Glandorf, Sophia Theres Pallenberg, Felix C. Ringshausen, Gesine Hansen, Diane Miriam Renz, Frank K. Wacker et al. · 2024 · Radiology Cardiothoracic Imaging
Structure-based discovery of CFTR potentiators and inhibitors
Fangyu Liu, Anat Levit Kaplan, Jesper Levring, Jürgen Einsiedel, Stephanie Tiedt, Katharina Distler, Natalie S. Omattage, Ivan S. Kondratov, Yurii S. Moroz, Harlan Linver Pietz et al. · 2024 · Cell
Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis
Steven Levitte, Yonathan Fuchs, Russell T. Wise, Zachary M. Sellers · 2023 · Hepatology Communications
Precision Medicine and Its Imprecise History
Christopher J. Phillips · 2020 · Harvard Data Science Review
Doenças raras na agenda da inovação em saúde: avanços e desafios na fibrose cística
Marise Basso Amaral, Sérgio Rêgo · 2020 · Cadernos de Saúde Pública
Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID‐19 pandemic
Patel, Shreya, Thompson, Misty D., Slaven, James E., Sanders, Don B., Ren, Clement L. · 2021 · Pediatric Pulmonology
The bidirectional relationship between CFTR and lipids
Kirsten A. Cottrill, Carlos Miguel Farinha, Nael A. McCarty · 2020 · Communications Biology
CFTR trafficking mutations disrupt cotranslational protein folding by targeting biosynthetic intermediates
Hideki Shishido, Jae Seok Yoon, Zhongying Yang, William R. Skach · 2020 · Nature Communications
Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy
Daniel M. Beswick, Stephen M. Humphries, Connor D. Balkissoon, Matthew J. Strand, Eszter K. Vladar, Vijay R. Ramakrishnan, Jennifer L. Taylor‐Cousar · 2021 · Journal of Cystic Fibrosis
A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators
Emily Kramer‐Golinkoff, Amanda Camacho, Liza Kramer, Jennifer L. Taylor‐Cousar · 2022 · Pediatric Pulmonology
Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis
Margarete Olivier, Alexandra Kavvalou, Matthias Welsner, Raphael Hirtz, Svenja Straßburg, Sivagurunathan Sutharsan, Florian Stehling, Mathis Steindor · 2023 · Frontiers in Pharmacology
Regulation of CFTR Biogenesis by the Proteostatic Network and Pharmacological Modulators
Samuel K. Estabrooks, Jeffrey L. Brodsky · 2020 · International Journal of Molecular Sciences
Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
Alice Tsai, Shu-Pei Wu, Eric L. Haseltine, Sanjeev Kumar, Samuel M. Moskowitz, Paul Panorchan, Kushal Shah · 2020 · Pulmonary Therapy
A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators
Elizabeth Marie Gavioli, Nerli Guardado, Farah Haniff, Nouran Deiab, Etty Vider · 2020 · Journal of Clinical Pharmacy and Therapeutics
Potential of the Electronic Nose for the Detection of Respiratory Diseases with and without Infection
Johann-Christoph Licht, Hartmut Grasemann · 2020 · International Journal of Molecular Sciences
Airway Epithelial Inflammation In Vitro Augments the Rescue of Mutant CFTR by Current CFTR Modulator Therapies
Martina Gentzsch, Deborah M. Cholon, Nancy L. Quinney, Mary E.B. Martino, John T. Minges, Susan E. Boyles, Tara N. Guhr Lee, Charles R. Esther, Carla M. P. Ribeiro · 2021 · Frontiers in Pharmacology
Correction of Airway Stem Cells: Genome Editing Approaches for the Treatment of Cystic Fibrosis
Nicholas E. King, Shingo Suzuki, C. Barillà, Finn J Hawkins, Scott H. Randell, Susan D. Reynolds, Barry R. Stripp, Brian R. Davis · 2020 · Human Gene Therapy
Biological insights in non-small cell lung cancer
Rafael Rosell, Anisha S Jain, Jordi Codony‐Servat, Eloisa Jantus Lewintre, Blake Morrison, Jordi Barretina, María González‐Cao · 2023 · Cancer Biology and Medicine
Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis
L.R. Caley, Heledd Jarosz-Griffiths, L. Smith, L. Gale, Joanne Barrett, Laura Kinsey, V. Davey, M. Nash, Andrew M. Jones, Joanna L. Whitehouse et al. · 2023 · Journal of Cystic Fibrosis
CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes
Juliet W. Lefferts, Marlou C. Bierlaagh, Suzanne Kroes, Natascha D.A. Nieuwenhuijze, Heleen N. Sonneveld van Kooten, Paul J Niemöller, Tibo F. Verburg, Hettie M. Janssens, Danya Muilwijk, Sam F.B. van Beuningen et al. · 2023 · International Journal of Molecular Sciences
Benchmarking AlphaMissense pathogenicity predictions against cystic fibrosis variants
McDonald, Eli Fritz, Oliver, Kathryn E., Schlebach, Jonathan P., Meiler, Jens, Plate, Lars · 2024 · PLOS ONE
Allele-Specific Prevention of Nonsense-Mediated Decay in Cystic Fibrosis Using Homology-Independent Genome Editing
Steven Erwood, Onofrio Laselva, Teija M.I. Bily, Reid A. Brewer, Alexandra H. Rutherford, Christine E. Bear, Evgueni A. Ivakine · 2020 · Molecular Therapy — Methods & Clinical Development
Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis
Julie Safirstein, Jonathan J. Grant, Emily Siu Clausen, Deepika Savant, Rebecca Dezube, Gina Hong · 2020 · Journal of Cystic Fibrosis
Challenges in the use of highly effective modulator treatment for cystic fibrosis
Kathleen J. Ramos, Joseph M. Pilewski, Jennifer L. Taylor‐Cousar · 2021 · Journal of Cystic Fibrosis
DNAJB12 and Hsp70 triage arrested intermediates of N1303K-CFTR for endoplasmic reticulum-associated autophagy
Lihua He, Andrew S. Kennedy, Scott A. Houck, Andrei A. Aleksandrov, Nancy L. Quinney, Alexandra Cyr-Scully, Deborah M. Cholon, Martina Gentzsch, Scott H. Randell, Hong Yu Ren et al. · 2021 · Molecular Biology of the Cell
Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype
Vito Terlizzi, Felice Amato, Chiara Castellani, Béatrice Ferrari, Luis J. V. Galietta, Giuseppe Castaldo, Giovanni Taccetti · 2021 · Molecular Genetics & Genomic Medicine
Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review
Jamie M Duckers, Beth A. Lesher, Teja Thorat, Eleanor J. Lucas, Lisa J. McGarry, Keval Chandarana, Fosca De Iorio · 2021 · Journal of Clinical Medicine
Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators
Carla M. P. Ribeiro, Matthew G. Higgs, Marianne S. Muhlebach, Matthew C. Wolfgang, Monica Borgatti, Ilaria Lampronti, Giulio Cabrini · 2023 · International Journal of Molecular Sciences
Bacteriophage Therapy for Pan-Drug-Resistant Pseudomonas aeruginosa in Two Persons With Cystic Fibrosis
Andrea Hahn, Iman R. Sami, Hollis R. Chaney, Anastassios C. Koumbourlis, Coralee Del Valle Mojica, Claire I. Cochrane, Benjamin K. Chan, Jonathan L. Koff · 2023 · Journal of Investigative Medicine High Impact Case Reports
Pharmacological approaches for targeting cystic fibrosis nonsense mutations
Jyoti Sharma, Kim M. Keeling, Steven Mark Rowe · 2020 · European Journal of Medicinal Chemistry
CRISPR/Cas9 gene editing therapies for cystic fibrosis
Carina Graham, Stephen L. Hart · 2021 · Expert Opinion on Biological Therapy
Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: Early report
Romain Bec, Martine Reynaud‐Gaubert, François Arnaud, Romain Naud, Nadine Desmazes Dufeu, Mathieu Di Biscéglie, Benjamin Coiffard, Jean‐Yves Gaubert, Julien Bermudez, Paul Habert · 2022 · European Journal of Radiology
Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis
Michael R. Beck, Douglas B. Hornick, Tahuanty A. Pena, Sachinkumar B. Singh, Brittany A. Wright · 2023 · Pediatric Pulmonology
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint
Pierre‐Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon, R. Kanaan, Jean Le Bihan, Natascha Remus, Bruno Ravoninjatovo, Dominique Grenet, Michele Porzio, Véronique Houdouin et al. · 2024 · European Respiratory Journal
Cystic fibrosis and primary ciliary dyskinesia: Similarities and differences
Rute Pereira, Telma Barbosa, Ana Lúcia Cardoso, Rosália Sá, Mário Sousa · 2023 · Respiratory Medicine
Personalized CFTR Modulator Therapy for G85E and N1303K Homozygous Patients with Cystic Fibrosis
Simon Y. Graeber, Anita Balázs, Niklas Ziegahn, Tihomir Rubil, Constanze Vitzthum, Linus Piehler, Marika Drescher, Kathrin Seidel, Alexander Rohrbach, Jobst Fridolin Roehmel et al. · 2023 · International Journal of Molecular Sciences
Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial
George Marty Solomon, Rachel W. Linnemann, Rachel Rich, Ashleigh Streby, B. Buehler, Eric Hunter, Kadambari Vijaykumar, William R. Hunt, John J. Brewington, András Rab et al. · 2024 · The Lancet Respiratory Medicine
Comparison of Organoid Swelling and In Vivo Biomarkers of CFTR Function to Determine Effects of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation
Simon Y. Graeber, Peter van Mourik, Annelotte M. Vonk, Evelien Kruisselbrink, Stephanie Hirtz, Cornelis Korstiaan van der Ent, Marcus Alexander Mall, Jeffrey Matthijn Beekman · 2020 · American Journal of Respiratory and Critical Care Medicine
CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis
Olaf Sommerburg, Susanne Hämmerling, S. Philipp Schneider, Jürgen G. Okun, Claus‐Dieter Langhans, Patricia Leutz-Schmidt, Mark Oliver Wielpütz, Werner Siems, Simon Y. Gräber, Marcus Alexander Mall et al. · 2021 · Antioxidants
A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants
Guido Veit, Tony Velkov, Haijin Xu, Nathalie Vadeboncoeur, Lara Bilodeau, Elias Matouk, Gergely L. Lukács · 2021 · Journal of Personalized Medicine
Family‐building and parenting considerations for people with cystic fibrosis
Traci M. Kazmerski, Natalie E. West, Raksha Jain, Ahmet Uluer, Anna M. Georgiopoulos, Moira L. Aitken, Jennifer L. Taylor‐Cousar · 2021 · Pediatric Pulmonology
Cancer in Cystic Fibrosis: A Narrative Review of Prevalence, Risk Factors, Screening, and Treatment Challenges
Patrick Maisonneuve, Albert B. Lowenfels · 2021 · CHEST Journal
CFTR and Gastrointestinal Cancers: An Update
Rahul Bhattacharya, Zachary Blankenheim, Patricia M. Scott, Robert T. Cormier · 2022 · Journal of Personalized Medicine
Weight a minute: Exploring the effect on weight and body composition after the initiation of elexacaftor/tezacaftor/ivacaftor in adults with CF
David Proud, Jamie M Duckers · 2023 · Journal of Cystic Fibrosis
Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor Treatment
Vincenzo Carnovale, Filippo Scialò, Monica Gelzo, Paola Iacotucci, Felice Amato, Federica Zarrilli, Assunta Celardo, Giuseppe Castaldo, Gaetano Corso · 2022 · Journal of Clinical Medicine
Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives
Young Jin Kim, Adrian R. Krainer · 2023 · Molecules and Cells
Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)
Alan Shi, Harold Nguyen, Chiaoyun Benson Kuo, Paul M. Beringer · 2024 · Journal of Cystic Fibrosis
Functional Consequences of CFTR Interactions in Cystic Fibrosis
Yashaswini Ramananda, Anjaparavanda P. Naren, Kavisha Arora · 2024 · International Journal of Molecular Sciences
The Precision Medicine Era of Bronchiectasis
Sanjay Haresh Chotirmall, James Duncan Chalmers · 2024 · American Journal of Respiratory and Critical Care Medicine
The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis
Lorenzo Guerra, Maria Favia, Sante Di Gioia, Onofrio Laselva, Arianna Bisogno, Valeria Casavola, Carla Colombo, Massimo Conese · 2020 · Expert Opinion on Drug Discovery
Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations
Munck, Anne, Kerem, Eitan, Ellemunter, Helmut, Campbell, Daniel, Wang, Linda T., Ahluwalia, Neil, Owen, Caroline A., Wainwright, Claire · 2020 · Journal of Cystic Fibrosis
Targeting the Heme Oxygenase 1/Carbon Monoxide Pathway to Resolve Lung Hyper-Inflammation and Restore a Regulated Immune Response in Cystic Fibrosis
Caterina Di Pietro, Hasan Halit Öz, Thomas S. Murray, Emanuela M. Bruscia · 2020 · Frontiers in Pharmacology
CFTR Modulators: Does One Dose Fit All?
Renske van der Meer, Erik B. Wilms, Harry G.M. Heijerman · 2021 · Journal of Personalized Medicine
A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients
Jia Xin Jiang, Leigh Wellhauser, Onofrio Laselva, Irina Utkina, Zoltán Bozóky, Tarini Nawamalie Abeysinghe Gunawardena, Zoe Ngan, Sunny Xia, Michelle Di Paola, Paul D. W. Eckford et al. · 2021 · Stem Cell Reports
Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19
Eunjin Hong, Lisa M. Almond, Peter S. Chung, Adupa P. Rao, Paul M. Beringer · 2022 · Clinical Pharmacology & Therapeutics
TMEM16A (ANO1) as a therapeutic target in cystic fibrosis
Luis J. V. Galietta · 2022 · Current Opinion in Pharmacology
Small-molecule eRF3a degraders rescue CFTR nonsense mutations by promoting premature termination codon readthrough
Rhianna E. Lee, Catherine A. Lewis, Lihua He, Emily C. Bulik‐Sullivan, Samuel C. Gallant, Teresa Mascenik, Hong Dang, Deborah M. Cholon, Martina Gentzsch, Lisa C. Morton et al. · 2022 · Journal of Clinical Investigation
Nutritional Status and Circulating Levels of Fat-Soluble Vitamins in Cystic Fibrosis Patients: A Cohort Study and Evaluation of the Effect of CFTR Modulators
Michela Francalanci, Vito Terlizzi, Cristina Fevola, G. Di Rosa, Valentina Pierattini, Elena Roselli, Paolo Bonomi, Maria Chiara Cavicchi, Valeria Galici, Anna Silvia Neri et al. · 2023 · Children
Cystic Fibrosis-Related Diabetes Workshop: research priorities spanning disease pathophysiology, diagnosis, and outcomes
Putman, Melissa S., Norris, Andrew W., Hull, Rebecca L., Rickels, Michael R., Sussel, Lori, Blackman, Scott M., Chan, Christine L., Ode, Katie Larson, Daley, Tanicia, Stecenko, Arlene A. et al. · 2023 · Diabetes Care
Impact of Elexacaftor–Tezacaftor–Ivacaftor on lung disease in cystic fibrosis
Courtney A. Gushue, Mariah Eisner, Shasha Bai, Terri Johnson, Melissa Holtzlander, Karen McCoy, Shahid Ijaz Sheikh · 2023 · Pediatric Pulmonology
Heterogeneity in response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
Gianfranco Alicandro, Andrea Gramegna, Federica Bellino, Calogero Sathya Sciarrabba, Chiara Lanfranchi, Martina Contarini, Mariangela Retucci, Valeria Daccò, Francesco Blasi · 2024 · Journal of Cystic Fibrosis
Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function
Pierre‐Régis Burgel, I. Durieu, R. Chiron, Laurent Mély, Anne Prévötat, M. Murris‐Espin, Michele Porzio, Michel Abély, Philippe Reix, Christophe Marguet et al. · 2020 · Journal of Cystic Fibrosis
Early Diagnosis and Intervention in Cystic Fibrosis: Imagining the Unimaginable
Andrea M. Coverstone, Thomas W. Ferkol · 2021 · Frontiers in Pediatrics
Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches
Alessandra Ghigo, Giulia Prono, Elisa Riccardi, Virginia De Rose · 2021 · International Journal of Molecular Sciences
Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review
Rosa María Girón Moreno, Marta María García Clemente, Layla Diab-Cáceres, Adrián Martínez-Vergara, Miguel Ángel Martínez‐García, Rosa Mar Gómez-Punter · 2021 · Antibiotics
Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease
B Bermingham, A. Rueschhoff, Gregory A. Ratti, Andrew NeSmith, Dana L. Goodwin, Shelly L. Gray, Patrick A. Flume, George Marty Solomon, Cohen L, Bryan A. Garcia · 2021 · Journal of Cystic Fibrosis
CFTR modulator use in post lung transplant recipients
Lauryn A. Benninger, Cesar Trillo‐Alvarez, Jorge E. Lascano · 2021 · The Journal of Heart and Lung Transplantation
Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series
Andrea Gramegna, Claudia De Petro, Gloria Leonardi, Martina Contarini, Francesco Amati, Roberto Meazza, Stefano Carugo, Francesco Blasi · 2022 · Journal of Cystic Fibrosis
Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis
Iris A. L. Silva, Onofrio Laselva, Miquéias Lopes‐Pacheco · 2022 · Journal of Personalized Medicine
Patient-derived cell models for personalized medicine approaches in cystic fibrosis
Anabela Santo Ramalho, Felice Amato, Martina Gentzsch · 2022 · Journal of Cystic Fibrosis
Moving the Dial on Airway Inflammation in Response to Trikafta in Adolescents with Cystic Fibrosis
Agathe Lepissier, Anne Sophie Bonnel, Nathalie Wizla, Laurence M. Weiss, Marie Mittaine, Katia Bessaci, Eitan Kerem, Véronique Houdouin, Philippe Reix, Christophe Marguet et al. · 2023 · American Journal of Respiratory and Critical Care Medicine
The role of modulators in cystic fibrosis related diabetes
Lina Merjaneh, Sana Hasan, Nader R. Kasim, Katie Larson Ode · 2021 · Journal of Clinical & Translational Endocrinology
Elexacaftor – Tezacaftor – Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study
Alexander Schnell, Hannah Hober, Natalie Kaiser, Renate Ruppel, Annika Geppert, Christina Tremel, Julia Sobel, Erika Plattner, Joachim Woelfle, André Hoerning · 2023 · Heliyon
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective
Nicole Mayer-Hamblett, John Paul Clancy, Raksha Jain, Scott H. Donaldson, Isabelle Fajac, Christopher Hooper Goss, Deepika Polineni, Felix A. Ratjen, Bradley S. Quon, Edith T. Zemanick et al. · 2023 · The Lancet Respiratory Medicine
Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care
Marian L. Henderson, Jacob K. Zieba, Xiaopeng Li, Daniel B. Campbell, Michael R. Williams, Daniel L. Vogt, Caleb P. Bupp, Yvonne M. Edgerly, Surender Rajasekaran, Nicholas Hartog et al. · 2024 · BioTech
Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians
Vito Terlizzi, Philip M. Farrell · 2024 · Current problems in pediatric and adolescent health care
Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor
Vito Terlizzi, Miquéias Lopes‐Pacheco · 2025 · Therapeutic Advances in Respiratory Disease
Phenotyping of Rare CFTR Mutations Reveals Distinct Trafficking and Functional Defects
Marjolein M. Ensinck, Liesbeth De Keersmaecker, Lise Heylen, Anabela Santo Ramalho, Rik Gijsbers, Ricard Farré, K. De Boeck, Frauke Christ, Zeger Debyser, Marianne Sylvia Carlon · 2020 · Cells
Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update
Marie E. Egan · 2020 · Current Opinion in Pediatrics
Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method
Felisa Reyes‐Ortega, Fiona Qiu, Elena K. Schneider‐Futschik · 2020 · ACS Pharmacology & Translational Science
The era of CFTR modulators: improvements made and remaining challenges
Sara Cuevas Ocaña, Onofrio Laselva, Julie Avolio, Raffaella Nenna · 2020 · Breathe